Company Filing History:
Years Active: 1993-2014
Title: Innovations of Carol E Cass: Pioneering Research on Nucleoside Transport
Introduction
Carol E Cass, an accomplished inventor based in Edmonton, Canada, has made significant contributions to the field of biotechnology. With a total of three patents to his name, his work primarily focuses on advancements related to nucleoside transport proteins, which play crucial roles in various biological processes.
Latest Patents
One of his latest patents, titled "Anti-human equilibrative nucleoside transporter 1 (hENT1) antibodies and methods of use thereof," introduces monoclonal antibodies that specifically recognize hENT1. This invention elaborates on methods that utilize these antibodies for therapeutic, diagnostic, and prophylactic applications in disorders characterized by altered hENT1 expression or activity.
Another significant patent details "cDNA encoding nucleoside transporter," which presents a comprehensive methodology for identifying compounds that can modulate the action of a Na⁺-dependent nucleoside transport polypeptide. This patent also encompasses isolated DNA coding for the transport polypeptide, techniques for its recombinant production, and specific antibodies and polynucleotide sequences targeting the polypeptide.
Career Highlights
Throughout his career, Carol E Cass has collaborated with prestigious institutions, notably the Governors of the University of Alberta and the University of Alberta itself. His research has contributed to the understanding of nucleoside transport mechanisms, paving the way for potential therapeutic interventions.
Collaborations
During his professional journey, he has had the opportunity to work alongside esteemed colleagues such as James D Young and Alan R Paterson. These collaborations have undoubtedly enriched his research endeavors and contributed to the groundbreaking innovations he has developed.
Conclusion
In conclusion, Carol E Cass stands out as a visionary inventor whose work has had a meaningful impact on the field of biotechnology. His patents regarding the hENT1 antibodies and nucleoside transport polypeptides underscore his commitment to advancing medical science, offering promising pathways for the treatment of various disorders related to nucleoside transport.